Macromolecular therapeutics have been developed to improve the efficacy and safety profile of varied therapeutic agents for different disease more than 50 years ago. N-(2-hydroxypropyl) methacrylamide (HPMA) copolymers as a drug delivery platform have been extensively studied and applied in the clinical trials. Recently, the application of HPMA copolymers in the treatment of non-cancerous diseases such like infectious diseases and musculoskeletal diseases has also been explored widely. In this chapter, different formulations of macromolecular therapeutics will be discussed. The design principles illustrated in the development of HPMA copolymer drug conjugates are also valid for other hydrophilic polymers, and they will be the principal focus of our discussion. Active targeting of HPMA copolymers based on targeting moieties and passively targeting HPMA copolymers based on the Enhanced Permeability and Retention (EPR) effect for cancer disease and Extravasation through Leaky Vasculature and subsequent Inflammatory cell-mediated Sequestration (ELVIS) mechanism for inflammation disease will also be discussed in this chapter.
- Cancer therapy
- Central nervous system (CNS)
- Hydroxypropyl methacrylamide HPMA copolymers
ASJC Scopus subject areas
- Immunology and Microbiology(all)
- Pharmacology, Toxicology and Pharmaceutics(all)